Evidence map›Paper›PMID 37293154›Full record

ArticleAmerican journal of cancer research2023

María Santos, Javier Lanillos, Eduardo Caleiras, Carlos Valdivia, Juan M Roldan-Romero, Nuria Laínez, Javier Puente, Benoit Beuselinck, Stéphane Oudard, Jessica Zucman-Rossi and 6 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Characterization ofCancers · 2024
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

María SantosHereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO) Madrid 28029, Spain.
Javier LanillosHereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO) Madrid 28029, Spain.
Eduardo CaleirasHistopathology Core Unit, Spanish National Cancer Research Centre (CNIO) Madrid 28029, Spain.
Carlos ValdiviaHereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO) Madrid 28029, Spain.
Juan M Roldan-RomeroHereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO) Madrid 28029, Spain.
Nuria LaínezDepartment of Medical Oncology, Complejo Hospitalario de Navarra Pamplona, Spain.
Javier PuenteMedical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC Madrid 28029, Spain.
Benoit BeuselinckDepartment of General Medical Oncology, Leuven Cancer Institute Leuven, Belgium.
Stéphane OudardDepartment of Medical Oncology, Hôpital Européen Georges Pompidou, AP-HP, University of Paris Paris, France.
Jessica Zucman-RossiINSERM UMR1138 Centre de recherche des Cordeliers, University of Paris Paris, France.
Paloma NavarroGenitourinary and Gynecological Cancer Unit, HM Hospitales-Centro Integral Oncológico HM Clara Campal Madrid 28029, Spain.
Mercedes RobledoHereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO) Madrid 28029, Spain.
Daniel CastellanoDepartment of Medical Oncology, University Hospital 12 de Octubre Madrid 28029, Spain.
Guillermo de VelascoDepartment of Medical Oncology, University Hospital 12 de Octubre Madrid 28029, Spain.
Jesús García-DonasGenitourinary and Gynecological Cancer Unit, HM Hospitales-Centro Integral Oncológico HM Clara Campal Madrid 28029, Spain.
Cristina Rodriguez-AntonaHereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO) Madrid 28029, Spain.
Centre for Biomedical Network Research on Rare Diseases · ESCentro de Investigación Biomédica en Red · ESComplejo Hospitalario de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) are key antiangiogenic drugs for renal cancer treatment. While Von Hippel-Lindau dysfunction constitutes the base for VEGFR-TKIs sensitivity, the role for individual and concurrent mutations in the genes encoding for the chromatin remodelers Polybromo-1 (

Indexed as

antiangiogenic responseClear cell renal cell carcinomaconcurrent mutationsKDM5CPBRM1tumor angiogenesis

Identifiers

PMID37293154
PMCPMC10244090
OpenAlexW4379966812

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.